Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SCCHO-ATP170 | Human | CHO/Human CD79A&CD79B Stable Cell Line | |||
| CDB-H52W3 | Human | Human CD79A&CD79B Heterodimer Protein, Mouse IgG2a Fc,Flag Tag&Mouse IgG2a Fc,His Tag (MALS verified) |  |
|
|
Expression analysis of human CD79A on CHO/Human CD79A&CD79B Stable Cell Line by FACS.
Intracellular staining was performed on CHO/Human CD79A&CD79B Stable Cell Line or negative control cell using FITC-labeled anti-human CD79A antibody after fixation and permeabilization.
Expression analysis of human CD79B on CHO/Human CD79A&CD79B Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human CD79A&CD79B Stable Cell Line or negative control cell using APC-labeled anti-human CD79B antibody.
The purity of Human CD79A&CD79B Heterodimer Protein, Mouse IgG2a Fc,Flag Tag&Mouse IgG2a Fc,His Tag (Cat. No. CDB-H52W3) is more than 85% and the molecular weight of this protein is around 110-150 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Polatuzumab vedotin | RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 | Approved | Seagen Inc, Genentech Inc | Polivy | United States | Lymphoma, Large B-Cell, Diffuse | Genentech Inc | 2019-06-10 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PRV-3279 | HDM-3002; MGD-010; PRV-3279; CD32BxCD79B | Phase 2 Clinical | Macrogenics Inc | Lupus Erythematosus, Systemic | Details |
| CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
| TolDCB29 | Phase 2 Clinical | Umc Utrecht | Arthritis, Rheumatoid | Details | |
| SHR-A1912 | SHR-A1912 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma | Details |
| CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
| Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy（MD Anderson Cancer Center） | JV-213 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Lymphoma | Details |
| NBT-508 | Phase 1 Clinical | Newbio Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| CD79b CAR-T cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute | Details |
This web search service is supported by Google Inc.
A-Z
